RZLT Stock Discussion

Rezolute, Inc. Description

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. Its products include RZ358, a human monoclonal antibody that is in Phase II clinical trial for the treatment of congenital hyperinsulinism, a devastating ultra-orphan pediatric disease; and RZ402, a plasma kallikrein inhibitor, which is in late stage preclinical program for the treatment of diabetic macular edema. It also develops AB101, a human recombinant insulin, which is in Phase I clinical trial for the treatment of patients with type 1 and type 2 diabetes mellitus. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Life Sciences Diabetes Cancer Treatment Monoclonal Antibody Metabolic Disease Insulin Specialty Drugs Diabetes Mellitus Diabetic Retinopathy Macular Edema Diabetic Macular Edema Kallikrein Plasma Kallikrein